ReviewInternational neurourology journal2016
Genetic and Epigenetic Alterations in Bladder Cancer.
Review in International neurourology journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed.
- Article
- Rapid establishment of KRAS-driven bladder cancer initiation and immune escape models using genetically engineered mice and organoid approaches.Frontiers in immunology · 2026Article
- Integrative Analysis Reveals the Prognostic Effects of Epigenetic Regulators in Bladder Cancer.Cancer medicine · 2025Article
- Emerging drivers of female bladder cancer: a pathway to precision prevention and treatment.Frontiers in oncology · 2025Article
- [High expression of miR-204-5p promotes malignant behaviors of bladder cancer cells by negatively regulating RAB22A].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024Article
- Article
- New synergistic combination therapy approaches with HDAC inhibitor quisinostat, cisplatin or PARP inhibitor talazoparib for urothelial carcinoma.Journal of cellular and molecular medicine · 2024Article
- Microbiome Sex-Related Diversity in Non-Muscle-Invasive Urothelial Bladder Cancer.Current issues in molecular biology · 2024Article
- Identification of Hydroxysteroid Dehydrogenase Type 1 As a Potential Bladder Tumor Marker.Iranian biomedical journal · 2024Article
- Bladder cancer biomarkers: current approaches and future directions.Frontiers in oncology · 2024Review
- A novel DNA methylation signature revealed GDF6 and RCC1 as potential prognostic biomarkers correlated with cell proliferation in clear cell renal cell carcinoma.Molecular biology reports · 2023Article
- Alternative polyadenylation-related genetic variants contribute to bladder cancer risk.Journal of biomedical research · 2023Article
- Epigenetic and Immunological Features of Bladder Cancer.International journal of molecular sciences · 2023Review
- Immunohistochemical expressions of EMT markers in pan-RAS-pERK1/2-positive tumors improve diagnosis and prognosis assessment of non-muscle invasive bladder cancer and muscle invasive bladder cancer patients.Molecular and cellular biochemistry · 2023Article
- FLI1 and FRA1 transcription factors drive the transcriptional regulatory networks characterizing muscle invasive bladder cancer.Communications biology · 2023Article
- H3 histone methylation landscape in male urogenital cancers: from molecular mechanisms to epigenetic biomarkers and therapeutic targets.Frontiers in cell and developmental biology · 2023Review
- Article
- Usefulness of the Urine Methylation Test (Bladder EpiCheckJournal of clinical medicine · 2022Article
- Sp1 is overexpressed and associated with progression and poor prognosis in bladder urothelial carcinoma patients.International urology and nephrology · 2022Article
- Novel intravesical therapeutics in the treatment of non-muscle invasive bladder cancer: Horizon scanning.Frontiers in surgery · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bladder cancer is one of the most common cancers worldwide, with a high rate of recurrence and poor outcomes as a result of relapse. Bladder cancer patients require lifelong invasive monitoring and treatment, making bladder cancer one of the most expensive malignancies. Lines of evidence increasingly point to distinct genetic and epigenetic alteration patterns in bladder cancer, even between the different stages and grades of disease. In addition, genetic and epigenetic alterations have been demonstrated to play important roles during bladder tumorigenesis. This review will focus on bladder cancer-associated genomic and epigenomic alterations, which are common in bladder cancer and provide potential diagnostic markers and therapeutic targets for bladder cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.